Last reviewed · How we verify
Paclitaxel dose escalation
At a glance
| Generic name | Paclitaxel dose escalation |
|---|---|
| Also known as | Taxol |
| Sponsor | Centre Oscar Lambret |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors (PHASE1)
- A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PHASE1)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (PHASE1, PHASE2)
- BBO-11818 in Adult Subjects With KRAS Mutant Cancer (PHASE1)
- KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |